(Alliance News) - Physiomics PLC on Monday said it has signed a further contract with Nasdaq-listed biopharmaceutical firm Bicycle Therapeutics.
The oncology consultant said the new contract is an extension of work it completed on Bicycle's BT1718 programme which is sponsored by Cancer Research. It added that its role is in relation to the analysis of clinical data from a phase I/IIa clinical trial of BT1718 in solid tumours
The project is set to be complete in the next six months. No financial details were disclosed.
"We are delighted to continue to expand our relationship with Bicycle Therapeutics, which is rapidly becoming a key high-profile client. It's also pleasing that we are able to sign new business in the current environment and hope to see this continue over the course of the rest of this calendar year," said Physiomics Chief Executive Jim Millen.
Physiomics shares closed 7.9% higher at 1.78 pence each on Monday in London.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)